• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts
    • MPR: Breakthrough Products Series
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Job Board
    • Leadership in Medtech
    • Manufacturer Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
    • DeviceTalks
  • Coronavirus: Live updates

Augmenix Inc.

Boston Scientific touts SpaceOAR meta-analysis results

June 18, 2020 By Sean Whooley

Boston Scientific (NYSE:BSX) announced that published results from an analysis of its SpaceOAR hydrogel spacer revealed safe prostate-rectum separation. Marlborough, Mass.-based Boston Scientific has developed the SpaceOAR since its $600 million acquisition of Augmenix in September 2018. The absorbable polyethylene glycol hydrogel spacer won CE Mark approval in the European Union in 2010 and 510(k) clearance from the […]

Filed Under: Clinical Trials, Featured, Men's Health, Oncology, Radiosurgery/Radiation therapy Tagged With: Augmenix Inc., Boston Scientific

Boston Scientific puts up $600m for Augmenix

September 7, 2018 By Brad Perriello

Boston Scientific (NYSE:BSX) said yesterday that it put $600 million on the table for Augmenix and its SpaceOar device. The deal for Bedford, Mass.-based Augmenix calls for $500 million in up-front cash and another $100 million pegged to sales-based milestones, Boston said. The SpaceOar hydrogel device, which won CE Mark approval in the European Union in 2010 […]

Filed Under: Mergers & Acquisitions, Urology, Wall Street Beat Tagged With: Augmenix Inc., Boston Scientific

Augmenix wins Japanese reimbursement for SpaceOar hydrogel

July 3, 2018 By Fink Densford

Augmenix said yesterday that its SpaceOar hydrogel won national reimbursement in Japan from the Ministry of Health, Labour & Welfare. The Belford, Mass.-based company’s SpaceOar hydrogel is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer. The product is delivered through a small needle as a liquid, which then solidifies […]

Filed Under: Business/Financial News, Orthopedics Tagged With: Augmenix Inc.

Augmenix touts AMA code, CMS reimbursement for SpaceOar

November 7, 2017 By Fink Densford

Augmenix said today that the American Medical Association established a Current Procedural Terminology code for its SpaceOar hydrogel and similar devices, with the Centers for Medicare and Medicaid Services setting a payment rate for procedures with the injectable. The Bedford, Mass.-based company said that the AMA established CPT code 55874 for the periprostatic implantation of biodegradable […]

Filed Under: Business/Financial News, Oncology Tagged With: Augmenix Inc.

Augmenix touts more SpaceOar data

February 24, 2017 By Sarah Faulkner

Augmenix touted data today from a Phase III trial evaluating its SpaceOar hydrogel in men undergoing prostate radiotherapy. The study showed that the company’s device, placed between the prostate and rectum, helps men maintain sexual function and potency following radiation therapy. Data from the trial demonstrated that the SpaceOar device reduced the median radiation dose […]

Filed Under: Clinical Trials, Urology Tagged With: Augmenix Inc.

Augmenix touts long-term data for hydrogel spacer in prostate cancer patients

January 3, 2017 By Sarah Faulkner

Augmenix Inc. said today that long-term outcomes data from the company’s phase III clinical trial evaluating its hydrogel spacer, SpaceOAR, was published in the International Journal of Radiation Oncology Biology and Physics. The spacer is designed to separate the rectum and prostate during prostate cancer radiotherapy, according to the Waltham, Mass.-based company. The newly published […]

Filed Under: Clinical Trials, Drug-Device Combinations, Oncology Tagged With: Augmenix Inc.

Augmenix scores reimbursement code for SpaceOar

November 9, 2016 By Fink Densford

Augmenix said today it won a category 1 current procedural terminology reimbursement code from the American Medical Association for periprostatic implantation of biodegradable material, covering its flagship SpaceOAR device. The SpaceOar is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer, Augmenix said. The device is delivered through a small needle […]

Filed Under: Business/Financial News, Urology Tagged With: Augmenix Inc.

Augmenix raises $6m in Series E round

July 13, 2016 By Fink Densford

Augmenix said today it raised $6 million in a Series E round of funding to support the development of next-gen products and support the company’s SpaceOAR system. The SpaceOar is designed to separate the prostate from the rectal wall during radiation treatment for prostate cancer, Augmenix said. The device is delivered through a small needle as a liquid, […]

Filed Under: Business/Financial News, Oncology Tagged With: Augmenix Inc.

Augmenix touts publication of pivotal SpaceOar study

June 15, 2015 By Fink Densford

Augmenix said last week that a pivotal study of its SpaceOar system was published online in the International Journal of Radiation Oncology•Biology•Physics. The 222-patient pivotal study was designed to evaluate safety and efficacy of the SpaceOar System in men undergoing prostate radiotherapy, the company said. The SpaceOar is designed to separate the prostate from the rectal wall during radiation […]

Filed Under: Clinical Trials, Radiosurgery/Radiation therapy, Urology Tagged With: Augmenix Inc.

On-X Life Technologies wins expanded labeling indication from FDA | Regulatory news for the week of April 6, 2015

April 7, 2015 By MassDevice Leave a Comment

FDA expands indication for On-X Life's heart valve

April 3, 2015 by Mark Hollmer

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance Tagged With: Augmenix Inc., Baxter, Biotronik, On-X Life Technologies, Philips

Augmenix wins FDA nod for SpaceOar prostate treatment

April 3, 2015 By Mark Hollmer

Augmenix wins FDA nod for SpaceOar prostate treatment

FDA clearance in hand, Augmenix is formulating U.S. commercial sales and insurance reimbursement plans for a medical gel designed to help protect the rectum during prostate cancer radiotherapy, CEP John Pedersen told MassDevice.com today.

Filed Under: Food & Drug Administration (FDA), News Well, Regulatory/Compliance, Urology Tagged With: Augmenix Inc., De Novo Clearance, Prostate

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by @MassDevice
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion

MASSDEVICE

Subscribe to MassDevice
Advertise with us
About
Contact us

Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS